Back
Compare AU
Compare ATOM vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X Uranium ETF (ATOM) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
ATOM | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 70 | 73 |
Median incremental investment | $1,000.00 | $660.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,892.56 | $1,696.50 |
Average age group | > 35 | > 35 |
Key Summary
ATOM | CURE | |
|---|---|---|
Strategy | ATOM.AX was created on 2022-12-07 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Global Uranium & Nuclear Components Total Return Index | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Cameco Corp (21.83 %) Oklo Inc Class A Shares (13.16 %) Sprott Physical Uranium Trust Units (5.75 %) | Avidity Biosciences Inc Ordinary Shares (2.45 %) Revolution Medicines Inc Ordinary Shares (2.36 %) Insmed Inc (2.14 %) |
Top 3 industries | Energy (57.48 %) Utilities (16.32 %) Industrials (11.79 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | Canada (47.95 %) United States (17.46 %) Australia (11.43 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.69 % | 0.45 % |
Key Summary
ATOM | CURE | |
|---|---|---|
Issuer | Global X | Global X |
Tracking index | Solactive Global Uranium & Nuclear Components Index | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.69 % | 0.45 % |
Price | $23.84 | $59.82 |
Size | $98.265 million | $38.099 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 2.08 % | 5.08 % |
Market | ASX | ASX |
First listed date | 06/12/2022 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
ATOM | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 70 | 73 |
Median incremental investment | $1,000.00 | $660.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,892.56 | $1,696.50 |
Average age group | > 35 | > 35 |
Pros and Cons
ATOM | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
ATOM | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |